MicroRNA-222 controls human pancreatic cancer cell line Capan-2 proliferation by P57 targeting

Journal of Cancer

Volumn 6, Issue 12, 2015, Pages 1230-1235

  Zhao, Yingying ^a   Wang, Yuqiong ^b,c   Yang, Yuefeng ^a,d   Liu, Jingqi ^a   Song, Yang ^a   Cao, Yan ^a   Chen, Xiaoyu ^a   Yang, Wenzhuo ^a   Wang, Fei ^a   Gao, Jun ^b   Li, Zhaoshen ^b   Yang, Changqing ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c No 411 Hospital of PLA   (China)

^d ZHEJIANG HOSPITAL   (China)

Author keywords

Capan 2; MicroRNA; MiR 222; P57; Pancreatic cancer; Proliferation

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1C; MICRORNA 222; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P27;

ARTICLE; CAPAN 2 CELL LINE; CELL COUNTING; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; PANCREATIC CANCER CELL LINE; PROTEIN EXPRESSION; PROTEIN TARGETING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 84954526892     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.12546     Document Type: Article

References (41)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin. 2003;53:5-26.
2. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281-97.
3. Liu X, Xiao J, Zhu H, Wei X, Platt C, Damilano F, et al. miR-222 Is Necessary for Exercise-Induced Cardiac Growth and Protects against Pathological Cardiac Remodeling. Cell Metab. 2015;21:584-95.
4. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435:834-8.
5. Li J, Bei Y, Liu Q, Lv D, Xu T, He Y, et al. MicroRNA-221 is required for proliferation of mouse embryonic stem cells via P57 targeting. Stem Cell Rev. 2015; 11:39-49.
6. Xiao J, Liang D, Zhang H, Liu Y, Zhang D, Liu Y, et al. MicroRNA-204 is required for differentiation of human-derived cardiomyocyte progenitor cells. J Mol Cell Cardiol 2012;53:751-9.
7. Ambros V. microRNAs: tiny regulators with great potential. Cell. 2001; 107: 823-6.
8. Xiao JJ, Shen B, Li J, Lv DC, Zhao YY, Wang F, et al. Serum microRNA-499 and microRNA-208a as biomarkers of acute myocardial infarction. Int J Clin Exp Med. 2014;7:136-41.
9. Roderburg C, Luedde T. Circulating microRNAs as markers of liver inflammation, fibrosis and cancer. J Hepatol. 2014;61:1434-7.
10. Xiao J, Jing ZC, Ellinor PT, Liang D, Zhang H, Liu Y, et al. MicroRNA-134 as a potential plasma biomarker for the diagnosis of acute pulmonary embolism. J Transl Med. 2011;9:159.
11. Li J, Xu J, Cheng Y, Wang F, Song Y, Xiao J. Circulating microRNAs as mirrors of acute coronary syndromes: MiRacle or quagMire? J Cell Mol Med. 2013; 17:1363-70.
12. Giray BG, Emekdas G, Tezcan S, Ulger M, Serin MS, Sezgin O, et al. Profiles of serum microRNAs; miR-125b-5p and miR223-3p serve as novel biomarkers for HBV-positive hepatocellular carcinoma. Mol Biol Rep. 2014;41:4513-9.
13. Xu J, Zhao J, Evan G, Xiao C, Cheng Y, Xiao J. Circulating microRNAs: novel biomarkers for cardiovascular diseases. J Mol Med (Berl). 2012;90:865-75.
14. Chen C, Zhang Y, Zhang L, Weakley SM, Yao Q. MicroRNA-196: critical roles and clinical applications in development and cancer. J Cell Mol Med. 2011;15:14-23.
15. Choi DH, Park SJ, Kim HK. miR-215 overexpression distinguishes ampullary carcinomas from pancreatic carcinomas. Hepatobiliary Pancreat Dis Int. 2015; 14: 325-9.
16. Ji Q, Hao X, Zhang M, Tang W, Yang M, Li L, et al. MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS One. 2009;4:e6816.
17. Kwon JJ, Nabinger SC, Vega Z, Sahu SS, Alluri RK, Abdul-Sater Z, et al. Pathophysiological role of microRNA-29 in pancreatic cancer stroma. Sci Rep. 2015; 5:11450.
18. Moriyama T, Ohuchida K, Mizumoto K, Yu J, Sato N, Nabae T, et al. MicroRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance. Mol Cancer Ther 2009;8:1067-74.
19. Park JK, Lee EJ, Esau C, Schmittgen TD. Antisense inhibition of microRNA-21 or-221 arrests cell cycle, induces apoptosis, and sensitizes the effects of gemcitabine in pancreatic adenocarcinoma. Pancreas. 2009;38:e190-199.
20. Wang P, Zhu CF, Ma MZ, Chen G, Song M, Zeng ZL, et al. Micro-RNA-155 is induced by K-Ras oncogenic signal and promotes ROS stress in pancreatic cancer. Oncotarget. 2015. [Epub ahead of print].
21. Xia X, Zhang K, Cen G, Jiang T, Cao J, Huang K, et al. MicroRNA-301a-3p promotes pancreatic cancer progression via negative regulation of SMAD4. Oncotarget. 2015. [Epub ahead of print].
22. Lee C, He H, Jiang Y, Di Y, Yang F, Li J, et al. Elevated expression of tumor miR-222 in pancreatic cancer is associated with Ki67 and poor prognosis. Med Oncol. 2013;30:700.
23. Mardente S, Mari E, Massimi I, Fico F, Faggioni A, Pulcinelli F, et al. HMGB1-Induced Cross Talk between PTEN and miRs 221/222 in Thyroid Cancer. Biomed Res Int. 2015;2015:512027.
24. Zhong C, Ding S, Xu Y, Huang H. MicroRNA-222 promotes human non-small cell lung cancer H460 growth by targeting p27. Int J Clin Exp Med. 2015;8:5534-40.
25. Ludwig N, Kim YJ, Mueller SC, Backes C, Werner TV, Galata V, et al. Posttranscriptional deregulation of signaling pathways in meningioma subtypes by differential expression of miRNAs. Neuro Oncol. 2015;doi:10.1093/neuonc/nov014.
26. Song C, Chen H, Wang T, Zhang W, Ru G, Lang J. Expression profile analysis of microRNAs in prostate cancer by next-generation sequencing. Prostate 2015;75: 500-16.
27. He HC, Han ZD, Dai QS, Ling XH, Fu X, Lin ZY, et al. Global analysis of the differentially expressed miRNAs of prostate cancer in Chinese patients. BMC Genomics. 2013;14:757.
28. Lee JC, Zhao JT, Clifton-Bligh RJ, Gill A, Gundara JS, Ip JC, et al. MicroRNA-222 and microRNA-146b are tissue and circulating biomarkers of recurrent papillary thyroid cancer. Cancer. 2013;119:4358-65.
29. Zhong S, Li W, Chen Z, Xu J, Zhao J. MiR-222 and miR-29a contribute to the drug-resistance of breast cancer cells. Gene. 2013;531:8-14.
30. Li Y, Liang C, Ma H, Zhao Q, Lu Y, Xiang Z, et al. miR-221/222 promotes S-phase entry and cellular migration in control of basal-like breast cancer. Molecules. 2014;19:7122-37.
31. Sun Y, Zhang B, Cheng J, Wu Y, Xing F, Wang Y, et al. MicroRNA-222 promotes the proliferation and migration of cervical cancer cells. Clin Invest Med. 2014; 37: E131.
32. Yang X, Yang Y, Gan R, Zhao L, Li W, Zhou H, et al. Down-regulation of mir-221 and mir-222 restrain prostate cancer cell proliferation and migration that is partly mediated by activation of SIRT1. PLoS One. 2014;9:e98833.
33. Yamashita R, Sato M, Kakumu T, Hase T, Yogo N, Maruyama E, et al. Growth inhibitory effects of miR-221 and miR-222 in non-small cell lung cancer cells. Cancer Med 2015;4:551-64.
34. LaBaer J, Garrett MD, Stevenson LF, Slingerland JM, Sandhu C, Chou HS, et al. New functional activities for the p21 family of CDK inhibitors. Genes & Development 1997;11:847-862.
35. Matsuoka S, Edwards MC, Bai C, Parker S, Zhang PM, Baldini A, et al. P57(KIP2), A Structurally distinct member of the P21(CIP1) CDK inhibitor family, is a candidate tumor-suppressor gene. Genes & Development 1995;9:650-662.
36. Fornari F, Gramantieri L, Ferracin M, Veronese A, Sabbioni S, Calin GA, et al. MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene 2008;27:5651-61.
37. Riccio O, van Gijn ME, Bezdek AC, Pellegrinet L, van Es JH, Zimber-Strobl U, et al. Loss of intestinal crypt progenitor cells owing to inactivation of both Notch1 and Notch2 is accompanied by derepression of CDK inhibitors p27(Kip1) and p57(Kip2). Embo Rep. 2008;9:377-83.
38. Liu X, Cheng Y, Yang J, Xu L, Zhang C. Cell-specific effects of miR-221/222 in vessels: molecular mechanism and therapeutic application. J Mol Cell Cardiol. 2012; 52:245-55.
39. Medina R, Zaidi SK, Liu C-G, Stein JL, van Wijnen AJ, Croce CM, et al. MicroRNAs 221 and 222 bypass quiescence and compromise cell survival. Cancer Res. 2008;68:2773-80.
40. Besson A, Dowdy SF, Roberts JM. CDK inhibitors: cell cycle regulators and beyond. Dev Cell. 2008;14:159-69.
41. Guo H, Tian T, Nan K, Wang W. p57: A multifunctional protein in cancer (Review). Int J Oncol. 2010;36:1321-9.